摘要
目的探讨厄洛替尼单药治疗晚期非小细胞肺癌的疗效及不良反应。方法对30例既往接受化疗失败非小细胞肺癌患者给予口服厄洛替尼150ml/天,直到疾病进展或其它原因停药。结果对本组30例患者进行评价疗效,总有效率为23.3%,疾病控制率76.7%,(0例CR,7例PR,16例SD)。未观察到疗效与性别、年龄、一般状况、吸烟、分期及既往治疗等临床特点有相关性。中位随访时间为(6周～63周)。厄洛替尼的不良反应可耐受,主要表现为皮疹。结论厄洛替尼治疗非小细胞肺癌有效,对于晚期非小细胞肺癌的疗效显著,不良反应轻微。
Objective to study the effi cacy and adverse events of Erlotinib for treatment for advanced non-small cell lung cancer.Method 30 patients were enrolled who had failed from previous chemotherapy take the Erlotinib 150mg per day .All the patients took Erlotinib 150mg per day untile to disease progress or else courses.Result all the patients can be evaluated,total effi cacy rate is 23.3%,disease control rate is 76.7%（ no patient CR,7cases PR,16 cases SD.NO relation between the effi cacy and sex,age,general condition,smoking,stage and previous therapy.Median following time is six weeks to sixty-three weeks.Main adverse effects of Erlotinib is rash.Conclusion erlotinib is effective for non-small cell lung cancer,especially for advanced non-small cell lung cancer,the adverse of Erlotinib is slighted,which can be endured.
出处
《当代医学》
2010年第14期153-154,161,共3页
Contemporary Medicine
关键词
非小细胞肺癌
厄洛替尼
靶向
治疗
non-small cell lung cancer
Erlotinib
Targeted
therapy
